The new vaccine is a combination of GSK’s already-approved vaccines Bexsero and Menveo and is designed to protect against meningitis and blood poisoning caused by the A, B, C, W, and Y ...
That hasn’t stopped Bexsero’s steady growth, with sales approaching the $1 billion threshold last year, while Menveo added another $430 million. Pfizer has been something of an also-ran in the ...
In February 2010, a quadrivalent conjugate vaccine (Menveo; Novartis Vaccines and Diagnostics) was approved by the US FDA to prevent invasive meningococcal disease caused by Neisseria meningitidis ...
GSK PLC on Tuesday announced a new positive opinion from the EU's European Medicine Agency's Committee for Medicinal ... Subscribe now to see this Premium News article from Alliance News ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback